Diversity in clinical research: public health and social justice imperatives

被引:18
|
作者
Varma, Tanvee [1 ]
Jones, Camara P. [2 ,3 ]
Oladele, Carol [4 ]
Miller, Jennifer [5 ]
机构
[1] Yale Sch Med, New Haven, CT USA
[2] Morehouse Sch Med, Dept Community Hlth & Prevent Med, Atlanta, GA 30310 USA
[3] Harvard Univ, Radcliffe Inst Adv Study, Cambridge, MA 02138 USA
[4] Yale Sch Med, Sect Gen Internal Med, New Haven, CT USA
[5] Yale Sch Med, Dept Internal Med, New Haven, CT USA
关键词
Clinical Trial; Ethics-; Medical; Public Policy; MOLECULAR ENTITY DRUGS; RACE; PARTICIPATION; TRIALS; PHARMACOKINETICS; MEDICINE; RACISM; FDA;
D O I
10.1136/medethics-2021-108068
中图分类号
B82 [伦理学(道德学)];
学科分类号
摘要
It is well established that demographic representation in clinical research is important for understanding the safety and effectiveness of novel therapeutics and vaccines in diverse patient populations. In recent years, the National Institutes of Health and Food and Drug Administration have issued guidelines and recommendations for the inclusion of women, older adults, and racial and ethnic minorities in research. However, these guidelines fail to provide an adequate explanation of why racial and ethnic representation in clinical research is important. This article aims to both provide the missing arguments for why adequate representation of racial and ethnic minorities in clinical research is essential and to articulate a number of recommendations for improving diversity going forward. Appropriate racial and ethnic representation and fair inclusion help (1) increase the generalisability of clinical trial results, (2) equitably distribute any benefits of clinical research and (3) enable trust in the research enterprise.
引用
收藏
页码:200 / 203
页数:4
相关论文
共 50 条